Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world

Patient Compliance - Cracking That Big Nut

Patient Compliance - Cracking That Big Nut

Mary Assimakopoulos, eyeforpharma 11th June 2013

In this month’s column we look at the issue of non-adherence, the risk of bias in adherence surveys and how a better understanding of true patient behavior is critical to improving compliance. Consider the scenario – the physician has been detailed, is sold on your brand and prescribes it to the patient. Unfortunately, the patient, perhaps unconvinced of the drug’s benefits, either doesn’t fill the prescription or fails to properly adhere to the treatment regime – that’s assuming they even present in the first place. The consequence for many patients is that they don’t get the best outcomes and end up with negative perceptions of the drug. The consequence for pharma, of course, is that drug sales are impacted and brand image is damaged. Non-adherence is a very common problem and a big issue for pharma, especially in chronic disease areas like diabetes, hypertension and osteoporosis. The pharmaceutical industry has invested significant time and money trying to solve this issue, particularly with the use of memory aids ranging from simple pill boxes to sophisticated wireless devices. But how effective are these aids? We recently undertook a study[i] to investigate compliance in type 2 diabetes. We were looking to address a…

read more »

  • Posted by Marc Yates
  • June 10, 2013
  • Articles

The Brazil Conundrum

The Brazil Conundrum

Published in PME June 2013 By Marc Yates, Director Asia Pacific and Emerging Markets

A rising middle class has seen healthcare challenges shift from a lack of affordability to discussions about willingness to spend. Predicted to become the world’s sixth-largest pharma market by 2014, there are many compelling reasons why the industry should be interested in Brazil. But this country is a conundrum because while it appears to be very large and increasingly attractive, it is also confusing, complex and marred by reports of corruption and inefficiencies. The health service is so complicated that many Brazilian nationals say even they have trouble understanding it!Economy Superintendent Joao Carles Gomes put it well when he stated: “This is a country with an excellent market and high demand. But it’s a pity it has such huge bureaucracy. Brazil is a great country when it works. ” Pharma companies interested in penetrating Brazil need answers to a number of questions if they are to be able to leverage the opportunities potentially on offer. These are four of the biggest. Question 1: is there universal access?The 1998 Brazilian constitution guarantees universal access to healthcare for all citizens, regardless of income. Currently 75% of healthcare provision is delivered by the public sector, yet 61% of healthcare spending is in the…

read more »

  • Posted by Olivia Richardson
  • June 3, 2013
  • Events

EphMRA Conference 2013

EphMRA Conference 2013

London, UK June 25 -27, 2013

We were delighted to exhibit at this year's EphMRA Conference in London, UK. Representing the Research Partnership were directors Angela Duffy, Sue Marrett and Sue Rees. 

read more »